Vaccine biotechnology company Novavax (NASDAQ: NVAX) will be announcing earnings results tomorrow before market open. Here’s what you need to know.
Novavax beat analysts’ revenue expectations last quarter, reporting revenues of $70.45 million, down 16.6% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ EPS estimates.
Is Novavax a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Novavax’s revenue to grow 5.9% year on year, a reversal from the 69.7% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Novavax has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Novavax’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen’s revenues decreased 7.1% year on year, beating analysts’ expectations by 3.6%, and Halozyme Therapeutics reported revenues up 51.6%, topping estimates by 0.6%. Biogen traded up 4.6% following the results while Halozyme Therapeutics was down 9%.
Read our full analysis of Biogen’s results here and Halozyme Therapeutics’s results here.
Investors in the therapeutics segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Novavax is down 3.8% during the same time and is heading into earnings with an average analyst price target of $13 (compared to the current share price of $9.45).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
